-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-033 in Chemotherapy Effects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-033 in Chemotherapy Effects report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-033 in Chemotherapy Effects Drug Details: MaaT-033 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-033 in Axial Spondyloarthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-033 in Axial Spondyloarthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-033 in Axial Spondyloarthritis Drug Details: MaaT-033 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-033 in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-033 in Amyotrophic Lateral Sclerosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-033 in Amyotrophic Lateral Sclerosis Drug Details: MaaT-033 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ZB-131 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ZB-131 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ZB-131 in Metastatic Pancreatic Cancer Drug Details: ZB-131 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neratinib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Neratinib in Pancreatic Cancer Drug Details: Neratinib (Nerlynx) is a member...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-013 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-013 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MaaT-013 in Metastatic Melanoma Drug Details:MaaT-013 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MaaT-013 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MaaT-013 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MaaT-013 in Graft Versus Host Disease (GVHD) Drug Details:...
-
Product Insights
NewHematopoietic Stem Cell Transplantation – Drugs In Development, 2024
Empower your strategies with our Hematopoietic Stem Cell Transplantation – Drugs In Development, 2024 report and make more profitable business decisions. Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from...
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...